NewsSource: EClinCloud

Product Overview | EDC · Clinical Trial Electronic Data Capture System

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration


Clinical trials often involve vast amounts of trial data. Due to quality and efficiency limitations, traditional collection methods can no longer meet pharmaceutical companies' pressing needs for cost reduction, efficiency gains, transformation, upgrading, and data verification, making digital and electronic data management an industry trend.


What Is EClinCloud EDC?

EClinCloud EDC is a next-generation electronic data capture system for clinical trials. Combining strengths from multiple international EDC systems with domestic user workflows, it enables electronic and intelligent data capture, remote data review, and transparent data standards, safeguarding the authenticity, reliability, integrity, and traceability of clinical trial data capture to substantially improve data quality and effectively shorten clinical study timelines.


What Are the Features of the EClinCloud EDC System?

Article illustration


What Are the Advantages of EClinCloud EDC?


01

Standardized Study Sites

Maintains standardized information for over 95% of study sites nationwide and supports easy site information lookup.


Article illustration


Article illustration


02

Zero-Code Logic Checks

Data managers can configure complex logic checks without knowing any programming language.


Article illustration



03

Complete Data Audit Trail

Tracks the date, time, reason for change, and other details for every electronic data record entered, modified, or deleted.


Article illustration



04

Robust Data Security

Granular user permission settings down to the module and function level; comprehensive data security and SOP system certifications; and complete technical data security solutions for both production and R&D environments.


Article illustration



What Services Does EClinCloud Provide?

Article illustration



| About EClinCloud |

EClinCloud is a healthcare and life sciences technology company rooted in China and serving the global market. Guided by its mission of "bringing effective treatments to patients through technological innovation" and driven by science and medicine, it integrates digital technology with life sciences data to build an end-to-end digital clinical trial cloud platform and provide technical solutions for clinical endpoint assessment, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.



Article illustration

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.